Drugs that contain Methylnaltrexone Bromide

1. List of Relistor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025 SALIX PHARMS Stable methylnaltrexone preparation
Apr, 2024

(1 year, 2 months from now)

US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 2 months from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 2 months from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Dec, 2030

(7 years from now)

Market Authorisation Date: 24 April, 2008

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

2. List of Relistor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(8 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(8 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone
Mar, 2031

(8 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(8 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(8 years from now)

Market Authorisation Date: 19 July, 2016

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in